Urologists and patients show resilience, but we must be better prepared in the future, says urologist R. Jonathan Henderson, MD.

Urologist's Perspective: COVID-19 provides tough decisions—and valuable lessons

Combination therapy is the first-line standard for metastatic renal cell carcinoma.

How to choose systemic therapy for metastatic RCC

Patients with cancer are particularly susceptible to negative consequences of COVID-19.

Next-generation sequencing identifies subtypes that may benefit from immune checkpoint inhibitors.

BLC with hexaminolevulinate can be an easily replicable procedure
in patients with non–muscle-invasive bladder cancer.